twitter   linkedin

KMT Hepatech, Inc. provides efficient and cost-effective in vivo research services utilizing our proprietary platform technology of small animal model, the KMT MouseTM.

The KMT MouseTM is a chimeric mouse model with humanized liver with stable human hepatocytes engraftment of up to 95 per cent.

We are proud to acknowledge that generated in KMT MouseTM drug therapy responses parallel those seen in humans during clinical trials.

Due to the expanding interest in the humanized liver mouse model across a wide range of drug development fields, the company now offers services in the following areas:

  • Infectious diseases, such as Hepatitis C, Hepatitis B and Malaria
  • Safety toxicity: early assessment of potential hepatotoxicity in in vivo settings prior to first-in-human studies
  • Characterization of human-type drug and lipoprotein metabolism in in vivo settings prior to first-in-human studies

KMT Hepatech, Inc. owns an international patent portfolio that includes coverage of the uPA chimeric mouse model of HCV infection and on the uPA chimeric mouse for all potential applications including HBV, malaria and studies of toxicity, drug and lipoprotein metabolism.

The KMT MouseTM is your essential tool for therapeutics and vaccine development.

News and Events

  1. In Vitro product Press Release image

    Human Hepatocytes from Chimeric Mouse for In Vitro Studies

    March 08 2017

    KMT Hepatech and In Vitro ADMET Laboratories to Offer New Product

  2. SOT and ToxExpo 2017 small image

    SOT 2017 Meeting and ToxExpo

    February 28 2017

    Meet KMT Hepatech representatives at the booth #2542

  3. BIO Europe Spring small image

    BIO Europe Spring 2017 partnering conference

    February 23 2017

    Meet KMT Hepatech representative in Barcelona, Spain on March 20-22

  4. »more